MDRX Stock Recent News
MDRX LATEST HEADLINES
Veradigm (MDRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Investors continue to be optimistic about Veradigm (MDRX) owing to its strategic alliances.
CHICAGO--( BUSINESS WIRE )--Veradigm Inc. (Nasdaq:MDRX), formerly Allscripts Healthcare Solutions Inc., announced today that Rick Poulton, Veradigm Chief Executive Officer, will present at the 2023 J.P. Morgan Healthcare conference on Wednesday, January 11, 2023 at 3:45 PST.
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
Allscripts Healthcare Solutions has done well to post sales and cash flow growth in recent quarters. The company still faces uncertainty and risks moving forward, but it's healthy and trading on the cheap.
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Jenny Gelinas - VP, IR Richard Poulton - CEO Thomas Langan - President and Chief Commercial Officer Leah Jones - CFO Conference Call Participants Stephanie Davis - SVB Securities Charles Rhyee - Cowen and Company Thomas Keller - RBC Capital Markets George Hill - Deutsche Bank Cynthia Motz - Goldman Sachs Eric Percher - Nephron Research Operator Greetings, and welcome to Allscripts' Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.
AllScripts (MDRX) delivered earnings and revenue surprises of 21.05% and 0.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
MDRX vs. OMCL: Which Stock Is the Better Value Option?